Research graph
References from A phase 1b/2 study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML. Local targets link to admitted publications; unresolved targets remain external evidence.
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): a state-of-the-art report on behalf of the International Consortium for MDS (icMDS)
10.1016/j.blre.2023.101128 · 2023 · External reference
Molecular International Prognostic Scoring System for myelodysplastic syndromes
10.1056/evidoa2200008 · 2022 · External reference
Revised International Prognostic Scoring System for myelodysplastic syndromes
10.1182/blood-2012-03-420489 · 2012 · External reference
International Scoring System for evaluating prognosis in myelodysplastic syndromes
10.1182/blood.v89.6.2079 · 1997 · External reference
Management of patients with lower-risk myelodysplastic syndromes
10.1038/s41408-022-00765-8 · 2022 · External reference
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial
10.1016/s0140-6736(23)00874-7 · 2023 · External reference
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial
10.1016/s0140-6736(23)01724-5 · 2024 · External reference
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
10.1016/s1470-2045(09)70003-8 · 2009 · External reference
Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the Alternative Dosing for Outpatient Treatment (ADOPT) trial
10.1200/jco.2008.19.6550 · 2009 · External reference
Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure
10.1200/jco.2011.35.8135 · 2011 · External reference
Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium
10.1002/cncr.29145 · 2015 · External reference
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial
10.1016/s1470-2045(16)00009-7 · 2016 · External reference
Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage
10.1038/ncomms10615 · 2016 · External reference
Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes
10.1038/ng.1031 · 2011 · External reference
SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)
10.1182/blood-2012-01-404863 · 2012 · External reference
SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition
10.1016/j.ccell.2015.04.006 · 2015 · External reference
Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes
10.1182/blood-2011-12-399337 · 2012 · External reference
Phase I first-in-human dose escalation study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms
10.1038/s41375-021-01328-9 · 2021 · External reference
E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial
10.1038/s41375-023-02050-4 · 2023 · External reference
Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes
10.1016/j.leukres.2023.107390 · 2023 · External reference
Phase I/II study of the clinical activity and safety of GSK3326595 in patients with myeloid neoplasms
10.1177/20406207241275376 · 2024 · External reference
The augmented R-loop is a unifying mechanism for myelodysplastic syndromes induced by high-risk splicing factor mutations
10.1016/j.molcel.2017.12.029 · 2018 · External reference
R-loops as cellular regulators and genomic threats
10.1016/j.molcel.2019.01.024 · 2019 · External reference
Spliceosome mutations induce R loop-associated sensitivity to ATR inhibition in myelodysplastic syndromes
10.1158/0008-5472.can-17-3970 · 2018 · External reference
SF3B1 mutations induce R-loop accumulation and DNA damage in MDS and leukemia cells with therapeutic implications
10.1038/s41375-020-0753-9 · 2020 · External reference
Discovery and characterization of AZD6738, a potent inhibitor of ataxia telangiectasia mutated and Rad3 related (ATR) kinase with application as an anticancer agent
10.1021/acs.jmedchem.8b01187 · 2018 · External reference
Replication stress signaling is a therapeutic target in myelodysplastic syndromes with splicing factor mutations
10.3324/haematol.2020.254193 · 2021 · External reference
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
10.1182/blood-2005-10-4149 · 2006 · External reference
PATRIOT: a phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours
2018 · External reference
Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes
2023 · External reference
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults
10.1182/blood-2014-10-607341 · 2015 · External reference
Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM
10.48550/arxiv.1303.3997 · External reference
Failure to detect mutations in U2AF1 due to changes in the GRCh38 reference sequence
10.1016/j.jmoldx.2021.10.013 · 2022 · External reference
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
10.1038/nbt.2514 · 2013 · External reference
Strelka2: fast and accurate calling of germline and somatic variants
10.1038/s41592-018-0051-x · 2018 · External reference
VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing
10.1101/gr.129684.111 · 2012 · External reference
A case of acute myeloid leukemia with promyelocytic features characterized by expression of a novel RARG-CPSF6 fusion
10.1182/bloodadvances.2017014183 · 2018 · External reference
CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing
10.1371/journal.pcbi.1004873 · 2016 · External reference
limma powers differential expression analyses for RNA-sequencing and microarray studies
10.1093/nar/gkv007 · 2015 · External reference
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles
10.1073/pnas.0506580102 · 2005 · External reference
Chronic immune response dysregulation in MDS pathogenesis
10.1182/blood-2018-03-784116 · 2018 · External reference
The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes
10.1182/blood-2018-10-844654 · 2019 · External reference
Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure
10.3324/haematol.2012.071050 · 2013 · External reference
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes
10.1002/ajh.26771 · 2023 · External reference
The schedule of ATR inhibitor AZD6738 can potentiate or abolish antitumor immune responses to radiotherapy
10.1172/jci.insight.165615 · 2023 · External reference
Abstract CT026: phase I study of AZD6738, an inhibitor of ataxia telangiectasia Rad3-related (ATR), in combination with olaparib or durvalumab in patients (pts) with advanced solid cancers
2018 · External reference
Bone marrow–confined IL-6 signaling mediates the progression of myelodysplastic syndromes to acute myeloid leukemia
10.1172/jci152673 · 2022 · External reference
Influence of TNF and IL6 gene polymorphisms on the severity of cytopenias in Argentine patients with myelodysplastic syndromes
10.1007/s00277-017-3036-4 · 2017 · External reference
Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions
10.1038/bcj.2017.85 · 2017 · External reference
Tyrosine phosphorylation of both STAT5A and STAT5B is necessary for maximal IL-2 signaling and T cell proliferation
10.1038/s41467-024-50925-6 · 2024 · External reference
ATR-mediated DNA damage responses underlie aberrant B cell activity in systemic lupus erythematosus
10.1126/sciadv.abo5840 · 2022 · External reference
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment
10.1038/s41467-024-45996-4 · 2024 · External reference
JMJD1C forms condensate to facilitate a RUNX1-dependent gene expression program shared by multiple types of AML cells
10.1093/procel/pwae059 · 2025 · External reference
CRISPR activation screening identifies VGLL3-TEAD1-RUNX1/3 as a transcriptional complex for PD-L1 expression
10.4049/jimmunol.2100917 · 2022 · External reference
Runx1 and RORγt cooperate to upregulate IL-22 expression in Th cells through its distal enhancer
10.4049/jimmunol.1800672 · 2019 · External reference
Interactions among the transcription factors Runx1, RORgammat and Foxp3 regulate the differentiation of interleukin 17-producing T cells
10.1038/ni.1663 · 2008 · External reference
p53 signaling in response to increased DNA damage sensitizes AML1-ETO cells to stress-induced death
10.1182/blood-2007-06-093682 · 2008 · External reference
Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors
10.1038/nm.3993 · 2015 · External reference
Cell-autonomous dysregulation of interferon signaling drives clonal expansion of SRSF2-mutant MDS stem/progenitor cells
10.1182/blood.2024025670 · 2025 · External reference
Age-related diseases of inflammation in myelodysplastic syndrome and chronic myelomonocytic leukemia
10.1182/blood.2021014418 · 2022 · External reference
The significance of CUX1 and chromosome 7 in myeloid malignancies
10.1097/moh.0000000000000699 · 2022 · External reference
R-loop accumulation in spliceosome mutant leukemias confers sensitivity to PARP1 inhibition by triggering transcription-replication conflicts
10.1158/0008-5472.can-23-3239 · 2024 · External reference
